COSCIENS Financial Statements From 2010 to 2026

CSCI Stock   2.10  0.06  2.78%   
COSCIENS Biopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing COSCIENS Biopharma's valuation are provided below:
Gross Profit
4.4 M
Profit Margin
(2.00)
Market Capitalization
8.6 M
Enterprise Value Revenue
0.1389
Revenue
9.4 M
We have found one hundred twenty available fundamental signals for COSCIENS Biopharma, which can be analyzed and compared to other ratios and to its rivals. Traders should compare all of COSCIENS Biopharma prevailing fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year. The COSCIENS Biopharma's current Market Cap is estimated to increase to about 7 M, while Enterprise Value is forecasted to increase to (5.9 M).

COSCIENS Biopharma Total Revenue

16.64 Million

Check COSCIENS Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among COSCIENS Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.9 M, Interest Expense of 99.3 K or Total Revenue of 16.6 M, as well as many indicators such as Price To Sales Ratio of 0.57, Dividend Yield of 0.0 or PTB Ratio of 0.46. COSCIENS financial statements analysis is a perfect complement when working with COSCIENS Biopharma Valuation or Volatility modules.
  
Build AI portfolio with COSCIENS Stock
Check out the analysis of COSCIENS Biopharma Correlation against competitors.
For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.

COSCIENS Biopharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets42.3 M40.3 M20.1 M
Slightly volatile
Short and Long Term Debt Total1.7 M2.7 M2.2 M
Slightly volatile
Other Current Liabilities5.2 M4.9 M1.7 M
Slightly volatile
Total Current Liabilities8.7 M8.3 M4.2 M
Slightly volatile
Total Stockholder Equity15.9 M15.1 M12.5 M
Slightly volatile
Property Plant And Equipment Net13.2 M12.6 M8.8 M
Slightly volatile
Accounts Payable2.9 M2.8 MM
Slightly volatile
Cash19.8 M18.9 MM
Slightly volatile
Non Current Assets Total13.5 M10 M10.4 M
Slightly volatile
Cash And Short Term Investments19.8 M18.9 MM
Slightly volatile
Net ReceivablesM2.8 M1.4 M
Slightly volatile
Common Stock Shares Outstanding3.1 MM1.8 M
Slightly volatile
Liabilities And Stockholders Equity42.3 M40.3 M20.1 M
Slightly volatile
Non Current Liabilities Total17.7 M16.9 M7.3 M
Slightly volatile
Inventory3.2 M3.1 M1.4 M
Slightly volatile
Other Stockholder Equity7.1 M3.8 M5.4 M
Slightly volatile
Total Liabilities26.5 M25.2 M7.6 M
Slightly volatile
Total Current Assets29 M27.6 M9.6 M
Slightly volatile
Short Term Debt350.6 K243.9 K602.8 K
Slightly volatile
Intangible AssetsK6.3 K283.2 K
Slightly volatile
Current Deferred Revenue131.1 K138 K907.7 K
Pretty Stable
Common Stock14.3 M25.9 M13.3 M
Slightly volatile
Good Will139.1 K156.5 K170.8 K
Slightly volatile
Long Term Debt37.7 K42.4 K46.3 K
Slightly volatile
Short and Long Term Debt85.5 K65 K113.3 K
Slightly volatile
Capital Lease ObligationsM2.1 M2.7 M
Slightly volatile
Net Invested Capital20.1 M11.8 M23.6 M
Slightly volatile
Property Plant And Equipment Gross20.8 M18.1 M25.5 M
Slightly volatile
Capital Stock19.6 M25.9 M17.6 M
Slightly volatile
Net Working Capital14.8 M19.3 M10.5 M
Slightly volatile

COSCIENS Biopharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.9 M1.8 M808.7 K
Slightly volatile
Interest Expense99.3 K148.3 K101.2 K
Slightly volatile
Total Revenue16.6 M15.9 M9.7 M
Slightly volatile
Gross Profit8.2 M7.8 M5.2 M
Slightly volatile
Other Operating Expenses48.4 M46.1 M14.1 M
Slightly volatile
Research Development4.9 M9.5 M2.4 M
Slightly volatile
Cost Of Revenue8.4 MM4.5 M
Slightly volatile
Total Operating Expenses39.9 M38 M9.6 M
Slightly volatile
Selling General Administrative12.6 M12 M3.9 M
Slightly volatile
Selling And Marketing Expenses26.1 K27.5 K88.4 K
Slightly volatile
Reconciled Depreciation1.6 M1.8 M1.5 M
Slightly volatile
Interest Income532.5 K507.1 K201.5 K
Slightly volatile

COSCIENS Biopharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow8.1 M7.7 M3.7 M
Slightly volatile
Depreciation1.9 M1.8 M831.9 K
Slightly volatile
Capital Expenditures1.1 MM1.6 M
Slightly volatile
Stock Based Compensation560.3 K533.6 K216.8 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.570.61.6684
Slightly volatile
PTB Ratio0.460.4940.8328
Slightly volatile
Days Sales Outstanding59.7575.2546.9235
Slightly volatile
Book Value Per Share3.284.596.9409
Slightly volatile
Invested Capital16.1 M18.1 M19.7 M
Slightly volatile
Average Payables520.3 K974.9 K1.1 M
Pretty Stable
Stock Based Compensation To Revenue0.01570.03030.0202
Very volatile
Capex To Depreciation0.790.835.1768
Slightly volatile
PB Ratio0.460.4940.8328
Slightly volatile
Inventory Turnover2.222.349.0912
Pretty Stable
Days Of Inventory On Hand201162148
Pretty Stable
Payables Turnover1.862.612.8523
Very volatile
Sales General And Administrative To Revenue0.720.680.3648
Slightly volatile
Average Inventory1.3 M1.3 M784.8 K
Slightly volatile
Research And Ddevelopement To Revenue1.310.690.2753
Slightly volatile
Capex To Revenue0.0920.09690.7594
Slightly volatile
Cash Per Share6.05.722.7049
Slightly volatile
Days Payables Outstanding137145183
Slightly volatile
Tangible Asset Value19 M21.4 M23.4 M
Slightly volatile
Intangibles To Total Assets3.0E-43.0E-40.0237
Slightly volatile
Current Ratio3.633.822.6085
Slightly volatile
Receivables Turnover7.555.029.8534
Pretty Stable
Shareholders Equity Per Share3.284.596.9409
Slightly volatile
Debt To Equity0.150.165.1499
Slightly volatile
Capex Per Share0.490.521.4146
Slightly volatile
Average Receivables1.1 M1.1 M938.3 K
Slightly volatile
Revenue Per Share3.054.814.9952
Slightly volatile
Interest Debt Per Share1.751.092.0557
Slightly volatile
Debt To Assets0.0720.07570.1849
Slightly volatile
Graham Number22.0721.0213.66
Slightly volatile
Operating Cycle266237236
Pretty Stable
Price Book Value Ratio0.460.4940.8328
Slightly volatile
Days Of Payables Outstanding137145183
Slightly volatile
Company Equity Multiplier2.282.420.005
Slightly volatile
Long Term Debt To Capitalization0.00240.00250.2259
Slightly volatile
Total Debt To Capitalization0.160.170.3082
Slightly volatile
Debt Equity Ratio0.150.165.1499
Slightly volatile
Quick Ratio3.223.392.1589
Slightly volatile
Net Income Per E B T1.111.161.1081
Slightly volatile
Cash Ratio2.152.041.4158
Slightly volatile
Days Of Inventory Outstanding201162148
Pretty Stable
Days Of Sales Outstanding59.7575.2546.9235
Slightly volatile
Price To Book Ratio0.460.4940.8328
Slightly volatile
Fixed Asset Turnover1.071.137.3939
Very volatile
Debt Ratio0.0720.07570.1849
Slightly volatile
Price Sales Ratio0.570.61.6684
Slightly volatile
Asset Turnover0.430.450.644
Slightly volatile
Gross Profit Margin0.380.440.4997
Very volatile
Price Fair Value0.460.4940.8328
Slightly volatile

COSCIENS Biopharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market CapM6.4 M10.9 M
Pretty Stable

COSCIENS Fundamental Market Drivers

About COSCIENS Biopharma Financial Statements

Investors use fundamental indicators, such as COSCIENS Biopharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although COSCIENS Biopharma's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue138 K131.1 K
Total Revenue15.9 M16.6 M
Cost Of RevenueM8.4 M
Stock Based Compensation To Revenue 0.03  0.02 
Sales General And Administrative To Revenue 0.68  0.72 
Research And Ddevelopement To Revenue 0.69  1.31 
Capex To Revenue 0.10  0.09 
Revenue Per Share 4.81  3.05 
Ebit Per Revenue(1.72)(1.63)

Currently Active Assets on Macroaxis

When determining whether COSCIENS Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of COSCIENS Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cosciens Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cosciens Biopharma Stock:
Check out the analysis of COSCIENS Biopharma Correlation against competitors.
For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.
You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of COSCIENS Biopharma. If investors know COSCIENS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about COSCIENS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.54)
Revenue Per Share
2.996
Quarterly Revenue Growth
0.176
Return On Assets
(0.17)
Return On Equity
(1.13)
The market value of COSCIENS Biopharma is measured differently than its book value, which is the value of COSCIENS that is recorded on the company's balance sheet. Investors also form their own opinion of COSCIENS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is COSCIENS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because COSCIENS Biopharma's market value can be influenced by many factors that don't directly affect COSCIENS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between COSCIENS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if COSCIENS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, COSCIENS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.